Credit Suisse Ag Editas Medicine, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 903,257 shares of EDIT stock, worth $2.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

903,257

Previous 896,476 0.76%

Holding current value

$2.2 Million

Previous $9.08 Million 26.2%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$7.03 - $11.07 $47,670 - $75,065	6,781 Added 0.76%	903,257 $6.7 Million
Q4 2023 Feb 08, 2024	SELL	$6.25 - $11.11 $1.54 Million - $2.73 Million	-245,865 Reduced 21.52%	896,476 $9.08 Million
Q3 2023 Nov 13, 2023	BUY	$6.92 - $9.31 $475,134 - $639,233	68,661 Added 6.39%	1,142,341 $8.91 Million
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $608,760 - $1.1 Million	95,717 Added 9.79%	1,073,680 $8.84 Million
Q1 2023 May 10, 2023	SELL	$7.03 - $11.53 $40,738 - $66,816	-5,795 Reduced 0.59%	977,963 $7.09 Million
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $138,278 - $219,550	-16,620 Reduced 1.66%	983,758 $8.73 Million
Q3 2022 Nov 10, 2022	SELL	$12.16 - $19.42 $610,371 - $974,786	-50,195 Reduced 4.78%	1,000,378 $12.2 Million
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $265,464 - $567,333	-26,573 Reduced 2.47%	1,050,573 $12.4 Million
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $88,366 - $173,405	6,276 Added 0.59%	1,077,146 $20.5 Million
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $119,315 - $182,321	-4,494 Reduced 0.42%	1,070,870 $28.4 Million
Q3 2021 Nov 12, 2021	BUY	$39.27 - $72.94 $1.65 Million - $3.07 Million	42,024 Added 4.07%	1,075,364 $44.2 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $4.1 Million - $7.43 Million	131,137 Added 14.54%	1,033,340 $58.5 Million
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $2.15 Million - $4.91 Million	54,224 Added 6.39%	902,203 $37.9 Million
Q4 2020 Feb 12, 2021	SELL	$27.07 - $84.35 $3.37 Million - $10.5 Million	-124,571 Reduced 12.81%	847,979 $59.5 Million
Q3 2020 Nov 13, 2020	SELL	$28.06 - $37.16 $1.26 Million - $1.67 Million	-45,033 Reduced 4.43%	972,550 $27.3 Million
Q2 2020 Aug 12, 2020	BUY	$18.5 - $34.34 $512,246 - $950,840	27,689 Added 2.8%	1,017,583 $30.1 Million
Q1 2020 May 13, 2020	BUY	$14.88 - $32.78 $292,272 - $643,864	19,642 Added 2.02%	989,894 $19.6 Million
Q4 2019 Feb 12, 2020	BUY	$19.49 - $32.63 $280,928 - $470,328	14,414 Added 1.51%	970,252 $28.7 Million
Q3 2019 Nov 12, 2019	SELL	$22.49 - $26.81 $728,833 - $868,831	-32,407 Reduced 3.28%	955,838 $21.7 Million
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $665,948 - $902,671	32,517 Added 3.4%	988,245 $24.5 Million
Q1 2019 May 14, 2019	SELL	$19.43 - $26.41 $146,152 - $198,656	-7,522 Reduced 0.78%	955,728 $23.4 Million
Q4 2018 Feb 13, 2019	BUY	$18.19 - $31.79 $3.28 Million - $5.73 Million	180,162 Added 23.01%	963,250 $21.9 Million
Q3 2018 Nov 13, 2018	BUY	$27.65 - $38.39 $6.28 Million - $8.72 Million	227,266 Added 40.89%	783,088 $24.9 Million
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $3.02 Million - $3.95 Million	-96,260 Reduced 14.76%	555,822 $19.9 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $8.26 Million - $12.2 Million	276,794 Added 73.76%	652,082 $21.6 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $5.55 Million - $7.95 Million	253,627 Added 208.47%	375,288 $11.5 Million
Q3 2017 Nov 14, 2017	SELL	$15.81 - $24.01 $1.04 Million - $1.58 Million	-65,922 Reduced 35.14%	121,661 $2.92 Million
Q2 2017 Aug 14, 2017	BUY	N/A	187,583	187,583 $3.15 Million

Others Institutions Holding EDIT

# of Institutions

247

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $168M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account